Jabil Guides Q3 In Line With Estimates; Q2 Results Top Estimates

RTTNews | 609天前
Jabil Guides Q3 In Line With Estimates; Q2 Results Top Estimates

(RTTNews) - While reporting preliminary, unaudited financial results for its second quarter on Thursday, Jabil Inc. (JBL) said it expects third-quarter earnings in a range of $1.50 to $1.90 per share and core earnings in a range of $1.70 to $2.10 per share on net revenues between $7.9 billion and $8.5 billion.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $1.88 per share on revenues of $8.14 billion for the quarter. Analysts' estimates typically exclude special items.

Looking ahead to fiscal 2023, the company now projects revenues of about $34.5 billion, while analysts expect revenues of $34.51 billion for the year.

For the second quarter, the company reported net income of $207 million or $1.52 per share, compared to $222 million or $1.51 per share in the prior-year quarter. Excluding items, adjusted earnings for the quarter was $1.88 per share, compared to $1.68 per share in the year-ago quarter.

Net revenue for the quarter increased to $8.13 billion from $7.55 billion in the same quarter last year.

The Street was looking for earnings of $1.85 per share on revenues of $8.09 billion for the quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
Jabil Again Boosts FY22 Outlook - Update

Jabil Again Boosts FY22 Outlook - Update

While reporting preliminary, unaudited financial results for the third quarter on Thursday, Jabil Inc. (JBL) raised its core earnings and revenue guidance for the full-year 2022, based on solid demand in key areas of its business. The company also provided financial outlook for the fourth quarter.
RTTNews | 882天前
FDA Approves PTC's Kebilidi As First Gene Therapy To Treat AADC Deficiency

FDA Approves PTC's Kebilidi As First Gene Therapy To Treat AADC Deficiency

The U.S. Food and Drug Administration approved PTC Therapeutics, Inc.'s Kebilidi (eladocagene exuparvovec-tneq) gene therapy for the treatment of aromatic L-amino acid decarboxylase or AADC deficiency. Kebilidi is the first FDA-approved gene therapy for the deficiency. PTC shares gained around 8.5 percent in the extended trading on the Nasdaq on Thursday.
RTTNews | 5小时32分钟前
Asian Markets Mostly Higher

Asian Markets Mostly Higher

Asian stock markets are trading mostly higher on Friday, despite the broadly negative cues from Wall Street overnight, as traders react to a bunch of upbeat economic data from the region, including upbeat GDP data from Japan. Regional gains remained very modest after the U.S. Fed said it would slash interest rates carefully amid inflation pressures. Asian markets ended mixed on Thursday.
RTTNews | 7小时48分钟前
China Industrial Output Rises 5.3% On Year In October

China Industrial Output Rises 5.3% On Year In October

Industrial production in China was up 5.3 percent on year in October, the National Bureau of Statistics said on Friday - slowing from 5.4 percent in September and missing expectations for 5.5 percent.
RTTNews | 9小时0分钟前
Japanese Market Significantly Higher

Japanese Market Significantly Higher

Snapping a three-session losing streak, the Japanese stock market is significantly higher on Friday, despite the broadly negative cues from Wall Street overnight. The benchmark Nikkei 225 is moving well above the 38,800 level, with gains across all sectors led by index heavyweights and technology stocks as traders reacted to solid domestic GDP data.
RTTNews | 9小时2分钟前